

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number  
**WO 03/032956 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 9/22**,  
9/52, 31/517, A61P 13/08

Sandwich, Kent CT13 9NJ (GB). **SMITH, Janet, Sarah** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(21) International Application Number: PCT/IB02/04040

(22) International Filing Date:  
30 September 2002 (30.09.2002)

(74) Agents: **HAYLES, James, R.** et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(26) Publication Language: English

(30) Priority Data:  
0124455.7 11 October 2001 (11.10.2001) GB

(71) Applicant (*for GB only*): **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except GB, US*): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DAVIS, John, Douglas** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **HUMPHREY, Michael, John** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **MACRAE, Ross, James** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL FORMULATIONS FOR THE CONTROLLED RELEASE OF 4-AMINO-6,7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1,2,3,4-TETRAHYDROISOQUINOL-2-YL)-5-(2-PYRIDYL) QUINAZOLINE

(57) Abstract: The invention provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)-quinazoline, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941-1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37 °C. Formulations according to the invention are suitable for the treatment of BPH.

WO 03/032956 A1



PHARMACEUTICAL FORMULATIONS FOR THE CONTROLLED RELEASE OF 4-AMINO-6,7-DIMETHOXY-2-(5-METHANESULFONAMIDO-1,2,3,4-TETRAHYDROISOQUINOL-2-YL)-5-(2-PYRIDYL)QUINAZOLINE

This invention relates to controlled-release oral pharmaceutical formulations of  $\alpha$  adrenergic receptor antagonist compounds, including 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline and pharmaceutically acceptable salts thereof.

Controlled-release oral pharmaceutical formulations are known. Their purpose is to modify the rate of drug release, for example to produce a constant rate of release of a drug into the gastrointestinal tract of a patient, or to delay the release of a drug into the gastrointestinal tract of a patient (see Gupta and Robinson, "Oral controlled release delivery", Chapter 6 in: Treatise on Controlled Drug Delivery, Editor A. Kydonieus, Dekker, New York, 1992).


Streubel *et al* (Journal of Controlled Release, 67 (2000) p101-110) disclose tablets of verapamil hydrochloride containing hydroxypropylmethyl cellulose and organic acids.

Many  $\alpha$  adrenergic receptor antagonist compounds have been described. They have been indicated in the treatment of hypertension, congestive heart failure, benign prostatic hyperplasia (BPH) and Raynaud's Syndrome. Prazosin and alfuzosin are examples of  $\alpha$  adrenergic receptor antagonist compounds, and controlled-release formulations of them are disclosed in International Patent Application WO 94/27582.

The treatment of BPH is of particular interest, and formulations containing antagonist compounds selective for the  $\alpha_1$  adrenergic receptor, especially the  $\alpha_{1A}$  subtype (formerly known as the  $\alpha_{1C}$  subtype) are of particular interest. Such a compound is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, and its pharmaceutically acceptable salts.

4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, and its pharmaceutically acceptable salts, are disclosed in International Patent Application WO 98/30560 (see in particular Example 19). The mesylate salt of the compound is disclosed in WO 01/64672 (e.g. see Example 2). Both WO 98/30560 and WO 01/64672 are incorporated herein by reference.

4-Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, and its pharmaceutically acceptable salts, are indicated in the treatment of benign prostatic hyperplasia. The free base has the following structure:



- 5 A problem that can arise in the oral administration of  $\alpha$  adrenergic receptor antagonist compounds is poor or unpredictable absorption of the compound from the gastrointestinal tract. Another problem that can arise is sudden drops in blood pressure, particularly when the drug is released too rapidly into the gastrointestinal tract. In WO 94/27582, the first problem was addressed by formulating the  $\alpha$  adrenergic receptor
- 10 antagonist compounds alfuzosin and prazosin so as to give a biphasic release profile. Release of the drugs in two portions was preferred, with the preferred ratio of the two portions being 3:7, so that a high concentration could be maintained in the colon, where absorption of the drugs was found to be poor.
- 15 Bioavailability testing of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, and its pharmaceutically acceptable salts, by the applicants (unpublished), gave surprising results in that absorption from the colon was found to be low, and highly variable. It was unexpectedly found that intersubject variability could be minimized by administering 4-amino-6,7-dimethoxy-2-(5-
- 20 methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, and its pharmaceutically acceptable salts, in a controlled-release dosage form which delivered the majority of the drug to the upper gastrointestinal tract. Surprisingly, unacceptable sudden drops in blood pressure were not observed, and yet blood concentrations in vivo were sufficiently sustained to allow once daily dosing.
- 25
- Therefore, according to the present invention, there is provided a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant,

diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000),  
5 pp 1941-1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37°C.

The dissolution apparatus and conditions mentioned above are believed to model the  
10 conditions in the upper gastrointestinal tract. By "upper gastrointestinal tract" is meant the portion of the gastrointestinal tract between the mouth and the ileo-caecal junction inclusive. Furthermore, the time taken for a swallowed item to reach the ileo-caecal junction and pass into the lower gastrointestinal tract is thought to be about 6 hours (see the lecture by Professor Sidney Phillips entitled 'Gastrointestinal physiology and its  
15 relevance to targeted drug delivery', given 22 April 1993 in Short Hills (New Jersey, USA) as part of the Capsugel Symposia series 'Current status on targeted drug delivery to the gastrointestinal tract', subsequently published as part of the Capsugel Library).

Therefore, the invention may be stated alternatively as a controlled-release  
20 pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-  
25 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, in the upper gastrointestinal tract of a patient.

Preferably, at least 30% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the  
30 pharmaceutically acceptable salt thereof, is released after 3 hours in the dissolution apparatus (or following ingestion).

Preferably, less than 30% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the  
35 pharmaceutically acceptable salt thereof, is released after 1 hour in the dissolution apparatus (or following ingestion).

Preferably, formulations according to the invention contain from 0.1mg to 20mg (for example 1 to 15 mg) of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof. It is preferred that such formulations are administered once a day to human patients.

In formulations according to the present invention, it is preferred that the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, in said dosage form is:

- (a) embedded in a matrix from which it is released by diffusion or erosion;
- (b) present in a multiparticulate core (sometimes referred to as a bead formulation);
- (c) released through an aperture provided in an impermeable coating (sometimes referred to as an osmotic formulation);
- (d) released through a coating of low aqueous solubility;
- (e) released through a semipermeable coating;
- (f) present as an ion exchange resin; or
- (g) released at specific points in the gastrointestinal tract by a pulsatile device.

Matrix, bead and osmotic formulations are of interest.

Dealing with each category in turn:

- (a) In matrix systems, the active compound is embedded or dispersed in a matrix of another material which serves to retard the release of the active compound into an aqueous environment. Suitable matrix materials include hydroxypropyl methylcellulose and hydroxypropyl cellulose. Matrix formulations according to the present invention preferably comprise high molecular weight (*i.e.* 85,000-95,000 mass units) hydroxypropyl methylcellulose. It will be apparent to those skilled in the art that release by diffusion and erosion can occur simultaneously.
- (b) In multiparticulate cores, the active compound is present in a number of particles which also contain adjuvants, diluents or carriers. Suitable adjuvants, diluents and carriers include microcrystalline cellulose (preferably having a nominal mean particle size of 50 $\mu$ m) and lactose. Typically, the blended ingredients are formed into a wet mass which is extruded and spheronized to form beads which are then dried. The particles may then be filled into capsules. Prior to encapsulation, the particles can

optionally be coated with a semipermeable or low solubility membrane [see (d) and (e) below].

(c) Impermeable coatings are applied to tablets containing the active compound. "Impermeable" means that no significant transport of the active compound can take place across the coating during the intended release period of the formulation, although water can pass through. Suitable materials include film-forming polymers and waxes [e.g. thermoplastic polymers such as poly(ethylene-covinyl acetate), poly(vinyl chloride), ethyl cellulose and cellulose acetate] and the coating thickness is preferably greater than 100µm. The aperture may be formed by drilling, or if the coated formulation is conical, by cutting off the tip.

(d) Coatings of low aqueous solubility include polymers. The solubility of such polymers may be pH-dependent, for example substantially insoluble at pH<5 (so that dissolution does not take place in the stomach) and water soluble at pH>5. Preferred pH-sensitive polymers include shellac, phthalate derivatives (including cellulose acetate phthalate, polyvinylacetate phthalate), polyacrylic acid derivatives, and vinyl acetate and crotonic acid copolymers.

(e) Semipermeable membrane coatings allow the active compound to diffuse across the membrane or through liquid filled pores within the membrane. Suitable coating materials include polymers such as cellulose ester or ether, and acrylic polymers. Preferred materials include ethyl cellulose, cellulose acetate and cellulose acetate butyrate.

(f) Resinates may be prepared by treating anionic ion exchange resin beads (for example sodium polystyrene sulphonate) with an acid addition salt of the active ingredient.

(g) Pulsatile devices have the capacity to release drug at various points of the gastrointestinal tract. They may depend on osmotic potential to trigger release (see US Patent N° 3,952,741) or erosion of polymeric material due to changes in pH or microbial degradation. Suitable polymeric materials include pectin [Rubinstein *et al*, 1991, Pectic salt as a colonic delivery system, *Proceed. Intern. Symp. Control. Rel. Bioact. Mater.*], methacrylate-galactomannan [Lehman *et al*, 1991, Methacrylate-galactomannan coating for colonic specific drug delivery, *ibid*], matter containing azobonds [Kopeckova *et al*, 1991, Bioadhesive polymers for colon specific drug delivery, *ibid*], chondroitin [Sintov *et al*, 1991, Colonic administration of indomethacin using modified chondroitin in a cannulated dog model, *ibid*], dextran hydrogels [Bronsted *et al*, 1993, A novel hydrogel system designed for controlled drug delivery to the colon, *ibid*], methacrylic acid copolymers [Siefke *et al*, 1993, β-Cyclodextrin matrix films for colon specific drug

delivery, *ibid*], and amylose [Milojevik *et al*, *In vitro* and *in vivo* evaluation of amylose coated pellets for colon specific drug delivery, *ibid*]. Delivery to specific points of the gastrointestinal tract may also be achieved using multilayered tablets [Gazzaniga *et al*, 1993, Time dependent oral delivery system for colon specific release, *ibid*], or hydrogel  
5 plugs in a capsule [Binns *et al*, Application of a pH-independent PEG-based hydrogel to afford pulsatile drug delivery].

Formulations wherein the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt  
10 thereof, is embedded in a matrix from which it is released by diffusion or erosion, are of particular interest. Preferably, such formulations comprise 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; one or more release rate modifiers; one or more organic acids; and one or more tableting excipients.

15 Release rate modifiers that may be mentioned include hydroxypropylmethyl cellulose, methyl cellulose, sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, polyethylene oxide, xanthan gum, carbomer, ammonio methacrylate copolymer, hydrogenated castor oil, carnauba wax, paraffin wax, cellulose acetate phthalate,  
20 hydroxypropylmethyl cellulose phthalate and methacrylic acid copolymer. Hydroxypropylmethyl cellulose is of particular interest.

Preferred hydroxypropylmethyl celluloses have one or preferably more than one of the following features:

- 25
- a number average molecular weight in the range of about 20,000 to about 250,000, such as 20,000 to 125,000, more especially 25,000 to 100,000 (for example 27,000 or 89,000)
  - a degree of methyl substitution in the range of about 15% to about 35 %, such as 19-30% (for example 19-24%)

30

  - a degree of hydroxy substitution in the range of about 2% to about 15%, such as 4-12% (for example 7-12%)
  - the nominal viscosity of a 2% aqueous solution lies in the range of about 50 to about 150,000 cps, such as 50 to 100,000 cps, more especially 50 to 15,000 cps (for example 75 to 5,000 cps).

35

A number of hydroxypropylmethyl cellulose polymers are available commercially under the brand name Methocel™, and some of those suitable for use in formulations according to the invention are given in the table that follows:

Methocel™ grade	Number average MW	Degree of methyl substitution	Degree of hydroxy substitution	Nominal viscosity of a 2% aqueous solution	USP designation
K4M	89,000	19-24%	7-12%	4,000cps	2208
K15M	125,000	"	"	15,000cps	"
K100M	215,000	"	"	100,000cps	"
K100LV	27,000	"	"	100cps	"
E4M	93,000	28-30%	7-12%	4,000cps	2910
E10M	113,000	"	"	10,000cps	"
F4M	90,000	27-30%	4-7.5%	4,000cps	2906

5

Methocel™ K100LV, and especially K4M, have characteristics of particular interest.

It will be apparent to those skilled in the art that the hydroxypropylmethyl cellulose may consist of molecules of different chain lengths, but that the average chain length gives a molecular weight in the range stated.

10

Tabletting excipients for use in formulations according to the invention may include diluents, such as lactose monohydrate and anhydrous calcium hydrogen phosphate, and lubricants, such as magnesium stearate.

15

Organic acids for use in formulations according to the invention are the pharmaceutically acceptable organic acids, or mixtures thereof, and may contain one or more carboxylic acid groups. Preferably, one or more of the organic acids has a pKa (or lower/lowest pKa, for di-/multicarboxylic acids) in the range of about 1.75 to about 5.5, such as 3.25-5.0, more especially 4.0-5.0 (for example 4.1-4.8).

20

Preferably, one or more of the organic acids present is selected from: adipic acid, ascorbic acid, aspartic acid, benzoic acid, citric acid, fumaric acid, glutamic acid, lactic acid, maleic acid, malic acid, mandelic acid, sorbic acid, succinic acid and tartaric acid.



More preferably one or more of the organic acids present is selected from: adipic acid, sorbic acid and succinic acid.

5 Preferably, just one organic acid is present. More preferably, the sole organic acid is adipic acid.

Preferably, the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, makes up about 0.05% to about 25%, such as 0.5-20% (for example 1-15%) by  
10 weight of the formulation, expressed as free base.

Preferably, the hydroxypropylmethyl cellulose makes up about 10% to about 60%, such as 15-50%, more especially 20-40% (for example 22.5-30%) by weight of the  
15 formulation.

Preferably, about 5% to about 40%, such as 10-30% (for example 15-25%) by weight of the formulation is made up of organic acid.

20 Matrix tablet formulations according to the invention may be colour coated. The percentages given above relate to proportions in tablets prior to any optional coating being applied.

Therefore, in a particularly preferred aspect, the invention provides a controlled release matrix tablet formulation comprising 1-15% by weight of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a  
25 pharmaceutically acceptable salt thereof, 15-50% by weight hydroxypropylmethyl cellulose, 5-15% by weight lactose monohydrate, 15-40% by weight anhydrous calcium hydrogen phosphate, 10-30% by weight adipic acid, and 0.5-2% magnesium stearate. Additionally, the matrix tablet may be provided with a colour coating (not taken into  
30 account in the above percentages).

The invention also provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable salt  
35 thereof; hydroxypropylmethyl cellulose; one or more organic acids; and one or more tableting excipients.

Formulations according to the invention, especially matrix formulations containing an organic acid, have the advantage that the rate of release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline therefrom in aqueous media is independent of the pH of the media. This is surprising, because 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline is a basic compound and so is expected to be more soluble (and hence to be released more rapidly) in acidic conditions (as found in the stomach) than in neutral conditions (as found in the lower portions of the gastrointestinal tract). However, in patients, the drug is not liberated all at once in the stomach, but is delivered along the length of the gastrointestinal tract. This leads to sustained release and prolonged action of the drug. Nevertheless, the formulations are very simple and so can be manufactured easily and at a comparatively low cost.

Therefore, the invention further provides such formulations characterized in that the rate at which the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, is released therefrom is substantially independent of the pH of the surroundings.

"Substantially independent of the pH of the surroundings" may be defined as meaning that when the release profile of a formulation is measured at pH 2 and pH 7.5, then the percentage of drug released at a certain time point following commencement of the dissolution test (for example 6 hours) does not differ under the two pH conditions by more than about 20%, such as not more than 15%, preferably not more than 10%, for example about 5%.

Preferably, the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline is present as a pharmaceutically acceptable salt, such as its mesylate salt.

According to another aspect of the invention, there is provided the use of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of benign prostatic hyperplasia, characterized in that the medicament is a controlled-release pharmaceutical formulation as defined above.

There is also provided a method of treatment of benign prostatic hyperplasia which comprises administering an effective amount of a controlled-release pharmaceutical formulation as defined above, to a patient in need of such treatment.

- 5 The invention further provides a process for the production of a pharmaceutical formulation containing 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; hydroxypropylmethyl cellulose; one or more organic acids; and one or more  
10 tableting excipients; which comprises mixing the ingredients; followed by pressing into tablets.

- P Artursson and J Karlsson described the use of monolayers of Caco-2 cells to generate apparent permeability coefficients (Papp values) for drug absorption across the intestinal epithelium in 'Correlation between oral drug absorption in humans and apparent drug  
15 permeability coefficients in human intestinal epithelial (Caco-2) cells', Biochemical and Biophysical Research Communications, Vol 175 (3), pp 880-885, 1991.

- It has now been found that the absorption of  $\alpha$  adrenergic receptor antagonist compounds, or pharmaceutically acceptable salts thereof, having Papp values less than  
20  $15 \times 10^{-6}$  cm/s, can be improved, and made more predictable, by delivering the majority of the compound to the upper gastrointestinal tract.

- Thus, in a broader aspect, the invention may be described as a controlled-release pharmaceutical formulation for oral administration comprising an  $\alpha$  adrenergic receptor  
25 antagonist compound, or a pharmaceutically acceptable salt thereof, the compound having a Papp value of less than  $15 \times 10^{-6}$  cm/s across a monolayer of Caco-2 cells; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the  $\alpha$  adrenergic receptor antagonist compound, or the pharmaceutically acceptable salt thereof, after 6 hours in  
30 Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941-1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37°C.

- 35 Preferably, when measuring the Papp value, the initial concentration of test compound in the donor chamber is at a relevant therapeutic concentration, for example 25 $\mu$ M. 4-

Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate was tested at this concentration and found to have a Papp value of  $11 \times 10^{-6}$  cm/s.

- 5 Besides 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, and its pharmaceutically acceptable salts, silodosin [also known as KMD-3213; see Drugs of the Future (2001), 26(6), 553-560] is an  $\alpha$  adrenergic receptor antagonist compound of interest.
- 10 The invention is illustrated by the following examples with reference to the accompanying drawings in which:
- Figure 1 shows the percentage of drug compound released v time from a formulation prepared according to Example 2 in a standard dissolution test under two different pH conditions; and
- 15 Figure 2 shows, under corresponding test conditions, the percentage of drug compound released v time from a formulation analogous to that prepared according to Example 2, but containing no adipic acid.

The following abbreviations may be used:

- 20 ATCC            American Type Culture Collection  
HBSS            Hanks balanced salt solution  
HPLC            high performance liquid chromatography  
HPMC            hydroxypropylmethyl cellulose  
LC-MS           liquid chromatography mass spectroscopy  
25 MEM            minimum essential medium  
Ph Eur           European Pharmacopoeia  
SRC            standard round convex

#### Examples 1-5

- 30 **Tablet formulations of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate containing Methocel™ K4M**

- The following table shows the ingredients for preparing five tablet formulations containing, respectively, 1, 3, 6, 9 and 12 mg of active ingredient, expressed as free  
35 base.

Ingredient (mg) (reference to standard)	Ex 1	Ex 2	Ex 3	Ex 4	Ex 5
4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate (Pfizer)	1.189 <sup>(1)</sup>	3.567	7.134	10.701	14.268
HPMC (Methocel K4M, Ph.Eur)	30.000	30.000	30.000	22.500	22.500
Lactose Monohydrate (Ph.Eur)	13.203	10.108	9.216	10.200	9.308
Calcium Hydrogen Phosphate, Anhydrous (Ph.Eur)	39.608	30.325	27.650	30.599	27.924
Adipic Acid [DAB <sup>(2)</sup> ]	15.000	25.000	25.000	25.000	25.000
Magnesium Stearate (Ph.Eur)	1.000	1.000	1.000	1.000	1.000
Tablet weight (mg)	100.000	100.000	100.000	100.000	100.000

<sup>(1)</sup> Equivalent to 1.0 mg 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, in the form of its free base

<sup>(2)</sup> DAB is the Deutsches Arzneibuch (German Pharmacopoeia)

5

#### Method

The adipic acid was first screened through a suitable screen (e.g. 500 micron). The lactose monohydrate, hydroxypropylmethyl cellulose, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate, the screened adipic acid and calcium hydrogen phosphate, anhydrous were then added to a suitable blender (e.g. a tumble mixer) and blended. The blend was screened through a suitable screen (e.g. 500 micron) and reblended. About 50% of the lubricant (magnesium stearate) was screened, added to the blend and blended briefly.

The blend was roller compacted through a suitable roller compactor. The ribbon blend was then granulated, by screening through a suitable screen (e.g. 500 micron) and reblended. The remaining lubricant was screened, added to the blend and blended briefly.

The granules were then tabletted using appropriate 6 mm tooling to give 6 mm standard round convex white tablets with no engraving, which were then de-dusted.

#### 10 Examples 6-8

**Tablet formulations of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate containing Methocel™ K100LV**

The following table shows the ingredients for preparing two tablet formulations containing, respectively, 9, 12 and 1 mg of active ingredient, expressed as free base.

Ingredient (mg) (reference to standard)	Ex 6	Ex 7	Ex 8
4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate (Pfizer)	10.702 <sup>(1)</sup>	14.269	1.189
HPMC (Methocel™ K100LV, Ph.Eur)	100.000	100.000	40.00
Lactose Monohydrate (Ph.Eur)	11.825	10.933	10.703
Calcium Hydrogen Phosphate, Anhydrous (Ph.Eur)	35.473	32.798	32.108
Adipic Acid [DAB]	40.000	40.000	15.000
Magnesium Stearate (Ph.Eur)	2.000	2.000	1.000
Tablet weight (mg)	200.000	200.000	100.000

- (1) Equivalent to 9.0 mg 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, in the form of its free base

#### Method

- 5 The tablets of Examples 6, 7 and 8 were prepared analogously to those of Examples 1 to 5. However, in Examples 6 and 7, 8 mm tooling was used so as to give 8 mm standard round convex white tablets.

#### **Example 9**

- 10 **Tablet formulation of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate containing Methocel™ K100M**

The following table shows the ingredients for preparing a tablet formulation containing 3 mg of active ingredient, expressed as free base.

15

Ingredient (mg) (reference to standard)	Ex 9
4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate (Pfizer)	3.567 <sup>(1)</sup>
HPMC (Methocel K100M, Ph.Eur)	40.000
Lactose Monohydrate (Ph.Eur)	7.608
Calcium Hydrogen Phosphate, Anhydrous (Ph.Eur)	22.825
Adipic Acid [DAB]	25.000
Magnesium Stearate (Ph.Eur)	1.000
Tablet weight (mg)	100.000

- (<sup>1</sup>) Equivalent to 9.0 mg 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, in the form of its free base

#### Method

- 5 The tablets of Example 9 were prepared analogously to those of Examples 1 to 5.

#### **Example 10**

##### **Dissolution studies at different pH**

- The dissolution test according to United States Pharmacopoeia 24 (2000), pp 1941-  
10 1943, "Apparatus 1" (incorporated herein by reference) was followed, but using a covered vessel of nominal capacity 5000 ml (internal diameter 150 mm, height 345 mm). Formulations prepared according to Example 2 were dissolved in an aqueous buffer of pH 2 (composition 0.01M HCl and 0.12M NaCl) and in an aqueous buffer of pH 7.5 (composition 0.06M KCl, 0.03M NaCl, 0.006M KH<sub>2</sub>PO<sub>4</sub> and 0.005M NaOH). The  
15 dissolution fluid volume was 3000ml, the temperature was 37°C, the rotation speed of the baskets was 100 rpm, and the drug compound released was detected by UV spectroscopy at a wavelength of 246nm. The percentage of active ingredient released v time is shown in Figure 1.

- 20 It can be seen that the release profile at pH 2 and the release profile at pH 7.5 are almost identical, indicating that when administered orally to a patient the formulation is likely to deliver drug along the length of the gastrointestinal tract, leading to sustained release and prolonged drug action.
- 25 For comparison, a formulation analogous to that of Example 2 was prepared, but which contained no adipic acid. The release profile of this formulation was measured at pH 2 and pH 7.5 as above and the percentage of drug compound released v time is shown in Figure 2. It can be seen that the release profile at pH 2 and the release profile at pH 7.5 are very different. Accordingly this formulation is not likely to deliver drug along the  
30 length of the gastrointestinal tract, and hence give sustained release and prolonged drug action, when administered orally to a patient.

#### **Example 11**

##### **Modified release bead formulation**



The modified release bead (or multiparticulate) formulation consists of bead cores, coated with a release rate modifying membrane, filled into a hard gelatine capsule shell. The bead core composition is detailed in Table 1, the final dosage form is detailed in Table 2.

5

Table 1: bead core ingredients

Ingredient	Specification	Weight (mg)
4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate <sup>a</sup>	Pfizer	1.189
Lactose monohydrate <sup>b</sup>	Ph. Eur /NF	73.811
Adipic acid	DAB	15.000
Microcrystalline cellulose <sup>c</sup>	Ph. Eur /NF	10.000
Water, Purified <sup>d</sup>	Ph. Eur	(26.000)
		100.000 .

a - equivalent to 1.000 mg 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline calculated on a theoretical activity of 84.1%

10

b - as Pharmatose 110M (particle size specification 0-20% less than 63 µm, 30-60% less than 100 µm, 75-90% less than 150 µm, 100% less than 315 µm)

c - as Avicel<sup>TM</sup> PH101

15 d - Removed during the drying step, does not appear in the final product.

Table 2: modified release bead ingredients

Ingredient	Specification	mg/unit
4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline <sup>a</sup> core beads	Pfizer	100.000
Ammonio Methacrylate Copolymer, Type B <sup>b</sup>	USP/NF.	16.200
Ammonio Methacrylate Copolymer, Type A <sup>c</sup>	USP/NF	1.800
Talc	Ph. Eur	9.000
Triethyl Citrate	USP/NF	3.600
Water, Purified <sup>d</sup>	Ph. Eur	(147.400)
Talc <sup>e</sup>	Ph. Eur	(5.000)
Total		130.600
Size 4 white opaque hard gelatine capsule shell		

a - equivalent to 1.000 mg 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline

5 b - as Eudragit<sup>™</sup> RS30D. Equivalent to 54g Eudragit<sup>™</sup> RS30D, an aqueous dispersion with a solids content of 30%w/w.

c - as Eudragit<sup>™</sup> RL30D. Equivalent to 6g Eudragit<sup>™</sup> RL30D, an aqueous dispersion with a

10 solids content of 30%w/w.

d – the water content is lost during the process and does not appear in the final product.

e –this talc is applied during processing to aid lubrication and is removed by sieving.

#### Manufacturing process

15

Bead cores were manufactured by extrusion & spheronisation. The ingredients listed in Table 1 were first blended using a blend-screen-blend process. The blend was then wet-granulated using a Peerless EG2 mixer. The resulting wet mass was then extruded through a Nica<sup>™</sup> 140 extruder (aperture size 1.0 mm), followed by spheronisation in a

Caleva™ spheroniser. The resulting cores were tray dried in an oven at 40°C for 22 hours.

A polymer dispersion was then coated onto the bead cores (size between 850 µm and 1.40 mm). The dispersion was prepared by mixing Eudragit™ RS30D and Eudragit™ RL30D polymers, talc and triethyl citrate. Water was also added to obtain a solids content of about 14%. Coating-runs were performed using a fluidised bed Strea coater with the Wurster column in place, at a rate of about 6 g/min, with an inlet air temperature of 40°C, an atomizing air pressure of 0.8 bar ( $8 \times 10^4$  N/m<sup>2</sup>), a fluidizing air setting of 4, a tubing size of 0.093" ID x 0.062" wall (2.3mm x 1.6mm) and a nozzle size of 1mm. After coating, coated cores were mixed with 5% talc and allowed to cure at 40°C for 31 hours. After curing, the talc was removed by sieving. The coated bead cores were then loaded into capsules (130.600 mg per capsule)

## Example 12

### Osmotic tablet formulation

A modified release osmotic formulation consisting of a bilayer tablet core, with an impermeable coat (as described above) having orifices in it to enable drug release was prepared using the ingredients listed in Table 3 (tablet core composition) and Table 4 (final dosage form) below.

Table 3: osmotic tablet core composition

Ingredient	Weight (mg/unit)
<b>Layer 1:</b>	
4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (free base)	10.000
Xylitab™ 200 <sup>d</sup>	92.000
Polyethylene oxide <sup>a</sup>	88.000
Sodium starch glycolate <sup>b</sup>	8.000
Magnesium stearate	2.000

<b>Layer 2:</b>	
Sodium starch glycolate <sup>b</sup>	37.200
Silicified microcrystalline cellulose <sup>c</sup>	12.400
Colouring (FD&C red #40)	0.250
Magnesium stearate	0.150
<b>Total</b>	<b>250.000mg</b>
Tablet shape: 11/32" (8.7mm) SRC	

a - as Polyox™ WSR-205

b - as Explotab™

c - as Prosolv™ SMCC 90

- 5 d - a mixture of xylitol (minimum 96.5%) and carboxymethyl cellulose sodium (maximum 2.0%), manufactured by Danesco sweeteners

Table 4: modified release osmotic composition

<b>Ingredient</b>	<b>Weight (mg/unit)</b>
4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline tablet core <sup>a</sup>	250.000
Cellulose acetate <sup>b</sup>	16.975
Polyethylene glycol <sup>c</sup>	7.275
<b>Total</b>	<b>274.250</b>
Description: 11/32" (8.7mm) SRC bilayer film coated tablet with 5 x 900µm holes in the drug face	

10

a - as detailed in Table 1

b - as manufactured by Eastman, type CA 398-10

c - having a nominal average molecular weight of 3350

### Manufacturing process

Bilayer tablet cores were manufactured via compression of two dry powder blends.  
5 Firstly, the excipients of Layer 1 (except magnesium stearate) were blended with 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, then screened through a suitable sieve, and blended again. The excipients of Layer 2 (except magnesium stearate) were also blended together, then screened through a suitable sieve and blended again. The lubricant magnesium  
10 stearate was then mixed into each blend. Both blends were then compressed together using a suitable tablet press, to form a bilayer tablet.

A film coat was applied to the tablets by spraying a polymer solution onto the tablet cores. The solution was prepared by mixing cellulose acetate, polyethylene glycol, water  
15 and acetone. Coating runs were performed using a suitable pan coater. After coating, 5 x 900µm holes were drilled through the coat on the drug face of the tablet.

### **Example 13**

#### **Dissolution studies**

20 A number of the formulations from the preceding Examples were tested in the dissolution test according to United States Pharmacopoeia 24 (2000), pp 1941-1943, "Apparatus 1", using 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric  
25 acid (pH 2) containing 0.7% w/v sodium chloride at 37°C (unless otherwise shown). The percentage of drug compound released was detected by UV spectroscopy at a wavelength of 246nm, and is shown in the following table.

### Results

30

Time (h)	Ex 1 '1mg 9h' n=6 <sup>c</sup>	Ex 2 '3mg 9h' n=6	Ex 3 '6mg 9h' n=6	Ex 4 '9mg 9h' n=6	Ex 8 '1mg 6h' n=6	Ex 9 '3mg 15h' n=6	Ex 11 <sup>a</sup> Bead n=3	Ex 12 <sup>b</sup> Osmotic n=3
0.0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
1.0	24.00	20.00	15.00	16.00	27.00	16.00	5.00	-
2.0	39.00	34.00	26.00	27.00	48.00	26.00	9.00	38.00
3.0	52.00	45.00	36.00	37.00	66.00	35.00	23.00	-
4.0	64.00	56.00	46.00	47.00	83.00	43.00	43.00	67.00
5.0	75.00	65.00	55.00	55.00	91.00	51.00	61.00	-
6.0	83.00	73.00	63.00	63.00	96.00	58.00	77.00	-
7.0	92.00	80.00	70.00	70.00	97.00	64.00	83.00	-
8.0	98.00	86.00	77.00	77.00	-	70.00	88.00	97.00
9.0	102.00	91.00	83.00	83.00	-	75.00	91.00	-
10.0	107.00	-	87.00	88.00	-	80.00	93.00	-
11.0	-	-	92.00	92.00	-	84.00	95.00	-
12.0	-	-	95.00	96.00	-	88.00	96.00	-
13.0	-	-	98.00	98.00	-	91.00	97.00	-
14.0	-	-	99.00	101.00	-	93.00	98.00	98.00
15.0	-	-	101.00	101.00	-	95.00	99.00	-

Notes:

<sup>a</sup> dissolution volume 1000 ml instead of 900 ml

- 5 <sup>b</sup> dissolution medium was changed to 0.035M NaCl, 0.026M KH<sub>2</sub>PO<sub>4</sub>, 0.064M KCl (pH 7.5 instead of pH 2) during the experiment, at 2 hours. In view of the low solubility of the drug at pH 7.5, drug release could not be measured directly. Therefore, at subsequent time points, one of the tablets was assayed for residual drug by dissolving in a recovery solution (pH 2) and analyzing the solution by UV spectroscopy at a wavelength of 246nm
- 10 and the amount of drug released calculated. In addition, the rotation speed was 50 rpm instead of 100 rpm throughout the run

<sup>c</sup> "n" values indicate the number of formulations tested to give a mean result

#### Example 14

#### 15 In vivo studies

A number of the formulations from the preceding Examples were administered to human subjects. Blood samples were taken at various time points and the concentration of the

drug in the plasma measured using HPLC followed by fluorescence detection. The cumulative percentage of drug absorbed was then estimated by deconvolution of the data, using a solution dose as a reference. The results are shown in the following table.

Time (h)	Ex 1 '1mg 9h' n=16 <sup>a</sup>	Ex 2 '3mg 9h' n=16	Ex 3 '6mg 9h' n=15	Ex 4 '9mg 9h' n=15	Ex 8 '1mg 6h' n=16	Ex 9 '3mg 15h' n=16
0.0	0.000	0.000	0.000	0.000	0.000	0.000
0.5	11.265	10.412	12.331	11.931	15.042	10.168
1.0	20.055	19.701	12.331	11.931	26.152	20.705
2.0	35.361	42.634	25.977	31.243	45.840	23.246
3.0	43.499	49.403	31.113	41.141	58.511	35.610
4.0	59.187	60.685	44.658	51.640	74.125	35.610
6.0	60.449	60.685	45.721	55.536	74.125	38.239
8.0	60.792	61.948	48.387	55.755	74.125	39.210
10.0	62.381	61.948	50.004	56.054	74.125	39.754
12.0	62.381	61.948	50.017	56.054	74.125	40.636
15.0	63.570	61.948	51.718	56.054	74.125	40.636
18.0	63.989	62.985	-	-	74.125	41.780
24.0	70.099	68.967	57.323	62.932	79.591	47.020

5 Notes:

a - n values indicate the number of patients receiving the formulation

The results show that the formulations of the invention have good bioavailability, and have a smooth, sustained release profile suitable for once daily dosing.

10

### Example 15

#### Measurement of Papp values

Caco-2 cells originating from a human colon carcinoma were obtained from the ATCC  
 15 (HTB-37) and were used between passage number 24-44. Cells were maintained in MEM with Earles salts containing 2 mM L-glutamine, 1mM sodium pyruvate, 1% (v/v) MEM non-essential amino acids (Gibco) and 20 % foetal calf serum (Sigma) at 37°C in an atmosphere of 5% CO<sub>2</sub> and 90% relative humidity. Falcon 24 well filter inserts (Becton Dickinson) were seeded with 4 x 10<sup>4</sup> cells/well. The medium was changed  
 20 every 2-3 days. The cells formed confluent, differentiated cell monolayers after 15 days and were used for transport studies between days 15-25.

The Caco-2 cells are grown on the filter supports to produce a monolayer with well defined and developed tight junctions. Mannitol is used in all experiments to monitor monolayer integrity and only monolayers with a mannitol flux rate  $<1 \times 10^{-8}$  cm/sec were used in these studies.

Transport studies were conducted in triplicate wells using drug concentrations of 25  $\mu$ M or lower in HBSS (Gibco). Test compounds were prepared as 25 micromolar solutions and 250  $\mu$ l aliquots added to the apical chamber while 1ml of HBSS was added to the basolateral chamber. The wells were incubated at 37°C on a Denley Wellmixx plate shaker and samples were removed from both the apical and basolateral chamber after 2 hours and assayed for drug content using LC-MS.

Transport data across the Caco-2 cell monolayers is expressed as Papp values. Papp values are calculated according to the equation disclosed by Artursson and Karlsson as follows:

$Papp = (dQ/dt) (1/AC_0)$ , wherein  $dQ/dt$  is the permeability rate,  $C_0$  the initial concentration in the donor chamber, and A the surface area of the monolayer.

When the starting concentration was 25  $\mu$ m, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate was found to have a Papp value of  $11 \times 10^{-6}$  cm/s.



**Claims:**

1. A controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941-1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37°C.
2. A formulation as claimed in claim 1, wherein at least 30% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, is released after 3 hours.
3. A formulation as claimed in claim 1 or claim 2, wherein less than 30% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, is released after 1 hour.
4. A controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, in the upper gastrointestinal tract of a patient.
5. A formulation as claimed in any one of the preceding claims, which contains from 0.1mg to 20mg of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof.
6. A formulation as claimed in any one of the preceding claims, wherein the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, in said dosage form is:


- (a) embedded in a matrix from which it is released by diffusion or erosion;
  - (b) present in a multiparticulate core;
  - (c) released through an aperture provided in an impermeable coating;
  - (d) released through a coating of low aqueous solubility;
  - 5 (e) released through a semipermeable coating;
  - (f) present as an ion exchange resin; or
  - (g) released at specific points in the gastrointestinal tract by a pulsatile device.
7. A formulation as claimed in claim 6, wherein the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a  
10 pharmaceutically acceptable salt thereof, is embedded in a matrix from which it is released by diffusion or erosion.
8. A formulation as claimed in claim 7, comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a  
15 pharmaceutically acceptable salt thereof; one or more release rate modifiers; one or more organic acids; and one or more tableting excipients.
9. A formulation as claimed in claim 8, wherein the release rate modifier is hydroxypropylmethyl cellulose.
10. A formulation as claimed in claim 9, wherein the hydroxypropylmethyl cellulose  
20 has a number average molecular weight in the range 20,000-250,000.
11. A formulation as claimed in claim 9 or claim 10, wherein the hydroxypropylmethyl cellulose has a degree of methyl substitution in the range of about 15% to about 35%.
12. A formulation as claimed in any one of claims 9 to 11, wherein the hydroxypropylmethyl cellulose has a degree of hydroxy substitution in the range of about  
25 2% to about 15%.
13. A formulation as claimed in any one of claims 9 to 12, wherein the nominal viscosity of a 2% aqueous solution of the hydroxypropylmethyl cellulose lies in the range of about 50 to about 150,000 cps.
14. A formulation as claimed in any one of claims 9 to 13, wherein one or more of the  
30 organic acids has a pKa (or lower/lowest pKa, for di-/multicarboxylic acids) in the range of about 1.75 to about 5.5.
15. A formulation as claimed in any one of claims 9 to 14, wherein one or more of the organic acids is selected from adipic acid, ascorbic acid, aspartic acid, benzoic acid, citric acid, fumaric acid, glutamic acid, lactic acid, maleic acid, malic acid, mandelic acid,  
35 sorbic acid, succinic acid and tartaric acid.
16. A formulation as claimed in any one of claims 9 to 15, wherein the tableting excipients comprise lactose monohydrate and anhydrous calcium hydrogen phosphate.

17. A formulation as claimed in any one of claims 9 to 16, wherein the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, makes up about 0.05% to about 25% by weight of the formulation, expressed in the form of its free base.
- 5 18. A formulation as claimed in any one of claims 9 to 17, wherein the hydroxypropylmethyl cellulose makes up about 10% to about 60% by weight of the formulation.
19. A formulation as claimed in any one of claims 9 to 18, which contains about 5% to about 40% organic acid by weight of the formulation.
- 10 20. A formulation as claimed in any one of claims 9 to 19, containing just one organic acid.
21. A formulation as claimed in claim 20, wherein the organic acid is adipic acid.
22. A formulation as claimed in any one of claims 9 to 21, characterized in that the rate at which the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydro-
- 15 isoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, is released therefrom is substantially independent of the pH of the surroundings.
23. A controlled release matrix tablet formulation comprising 1-15% by weight of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof, 15-50% by weight
- 20 hydroxypropylmethyl cellulose, 5-15% by weight lactose monohydrate, 15-40% by weight anhydrous calcium hydrogen phosphate, 10-30% by weight adipic acid, and 0.5-2% magnesium stearate.
24. A formulation as claimed in any one of the preceding claims, wherein the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-
- 25 pyridyl)quinazoline is present as its mesylate salt.
25. Use of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of benign prostatic hyperplasia, characterized in that the medicament is a formulation as defined in any one of claims 1
- 30 to 24.
26. A method of treatment of benign prostatic hyperplasia, which comprises administering a formulation as defined in any one of claims 1 to 24 to a patient in need of such treatment.
27. A process for the production of a pharmaceutical formulation as defined in any
- 35 one of claims 9 to 24, which comprises mixing: 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof (such as the mesylate salt);

hydroxypropylmethyl cellulose; one or more organic acids (such as adipic acid); and one or more tableting excipients; followed by pressing into tablets.


28. A controlled-release pharmaceutical formulation for oral administration comprising an  $\alpha$  adrenergic receptor antagonist compound, or a pharmaceutically acceptable salt thereof, the compound having a Papp value of less than  $15 \times 10^{-6}$  cm/s across a monolayer of Caco-2 cells; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the  $\alpha$  adrenergic receptor antagonist compound, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941-1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37°C.

Figure 1



5

Figure 2



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/04040

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/22 A61K9/52 A61K31/517 A61P13/08

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 1 123 705 A (PFIZER) 16 August 2001 (2001-08-16) the whole document page 5, column 8, line 17 - line 37 ---	1-27
A	WO 01 64672 A (PFIZER) 7 September 2001 (2001-09-07) cited in the application the whole document ---	1-27
A	WO 98 30560 A (PFIZER) 16 July 1998 (1998-07-16) cited in the application the whole document ---	1-27
X	EP 0 466 986 A (BEND RESEARCH, INC.) 22 January 1992 (1992-01-22) page 8, column 14; example 19 --- -/--	28

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

11 December 2002

Date of mailing of the international search report

19/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 02/04040

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 752 737 A (SYNTHÉLABO SA ET AL.) 6 March 1998 (1998-03-06) page 1, line 1 - line 21 page 17 -page 20; example 3 page 19; table 5 -----	28

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IB 02/04040

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claim 26 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/04040

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1123705	A	16-08-2001	AU 1832901 A	16-08-2001
			CA 2334460 A1	09-08-2001
			EP 1123705 A1	16-08-2001
			HU 0100586 A2	28-11-2001
			NZ 509807 A	27-09-2002
			US 2001044438 A1	22-11-2001
WO 0164672	A	07-09-2001	AU 3588801 A	12-09-2001
			WO 0164672 A1	07-09-2001
			NO 20024195 A	03-09-2002
			US 2002010188 A1	24-01-2002
WO 9830560	A	16-07-1998	AP 819 A	03-04-2000
			AU 724990 B2	05-10-2000
			AU 6208898 A	03-08-1998
			BG 103560 A	30-06-2000
			BR 9807068 A	02-05-2000
			CN 1093858 B	06-11-2002
			WO 9830560 A1	16-07-1998
			EP 0968208 A1	05-01-2000
			HR 980010 A1	31-10-1998
			HU 0000942 A2	28-04-2001
			JP 2000507966 T	27-06-2000
			NO 993396 A	09-07-1999
			NZ 336302 A	25-08-2000
			PL 334678 A1	13-03-2000
			SK 90799 A3	12-03-2001
			TR 9901604 T2	21-12-1999
			TW 444013 B	01-07-2001
			US 2002040028 A1	04-04-2002
			US 6169093 B1	02-01-2001
			US 6365599 B1	02-04-2002
			ZA 9800166 A	09-07-1999
EP 466986	A	22-01-1992	AT 104826 T	15-05-1994
			CA 2014595 A1	12-10-1991
			DE 69008526 D1	01-06-1994
			DE 69008526 T2	18-08-1994
			EP 0466986 A1	22-01-1992
			ES 2053120 T3	16-07-1994
			US 5888930 A	30-03-1999
FR 2752737	A	06-03-1998	FR 2752737 A1	06-03-1998
			AT 200864 T	15-05-2001
			AU 724490 B2	21-09-2000
			AU 4020197 A	19-03-1998
			BG 103138 A	30-09-1999
			BR 9713237 A	04-04-2000
			CN 1228700 A	15-09-1999
			CZ 9900655 A3	16-06-1999
			DE 69704712 D1	07-06-2001
			DE 69704712 T2	29-11-2001
			DK 938318 T3	20-08-2001
			EE 9900090 A	15-10-1999
			EP 0938318 A1	01-09-1999
			ES 2159400 T3	01-10-2001
			WO 9808515 A1	05-03-1998
			GR 3036291 T3	31-10-2001

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/04040

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2752737      A		HK      1020875 A1	23-11-2001
		IL      128146 A	11-01-2001
		JP      2000514462 T	31-10-2000
		KR      2000035929 A	26-06-2000
		NO      990944 A	27-04-1999
		NZ      334018 A	29-06-1999
		PL      331862 A1	16-08-1999
		PT      938318 T	30-10-2001
		RU      2183459 C2	20-06-2002
		SI      938318 T1	31-12-2001
		SK      27099 A3	10-12-1999
		TR      9900289 T2	21-12-2000
		US      6149940 A	21-11-2000
		ZA      9707766 A	23-02-1998
<hr/>			